The KINOMEscan assay platform is based on a competition binding assay that is run for a compound of interest against each of a panel of 442 kinases. The assay has three components: a kinase-tagged pha
Three sets of approved drugs with associated activity data at varying confidence levels are provided. Approved drugs are taken from DrugBank. Each drug in each set is associated with ChEMBL activity r
